TSA v RSA in Osteoarthritic Shoulders With Greater Than 15 Degrees of Retroversion

What this study is about

This study will compare total shoulder arthroplasty (TSA) with an augmented glenoid component and reverse shoulder arthroplasty (RSA) procedures, in participants with advanced glenohumeral osteoarthritis aged 65 years and older, who also present with greater than 15 degrees of glenoid retroversion, in the context of a prospective, randomized controlled trial to determine the optimal treatment in this patient population.

Who can join (things the study team will check)

✅ You may be able to join if…

• Diagnosis of idiopathic shoulder OA.
• Patients who have failed standard non-surgical management of their shoulder OA who would benefit from a shoulder arthroplasty. Failed medical management will be defined as persistent pain and disability despite adequate standard non-operative management for at least 6 months. Medical management will be defined as: a) The use of drugs including analgesics and nonsteroidal anti-inflammatory drugs, b) Physiotherapy consisting of stretching, strengthening and local modalities (ultrasound, cryotherapy, etc.), c) Activity modification
• Imaging, and intra-operative findings confirming advanced glenohumeral cartilage loss
• Patients with a glenoid deficiency and >15 degrees of glenoid retroversion up to a maximum of 26 degrees of glenoid retroversion (i.e. -15.1, -17, -20…etc.)
• 65 years of age and older

🚫 You may not be able to join if…

• Active joint or systemic infection
• Rotator cuff arthropathy
• Significant muscle paralysis
• Charcot's arthropathy
• Major medical illness (life expectancy less than 1 year or unacceptably high operative risk)
• Unable to understand the consent form/process
• Pregnancy
• Psychiatric illness that precludes informed consent
• Unwilling to be followed for the duration of the study
• Retroversion cannot be surgically corrected to within 10 degrees of neutral
• History of previous shoulder surgery on affected side
• Rheumatoid arthritis in the affected shoulder

Where this trial is running

• Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Who to contact

Katie McIlquham · 613-737-8899 · kmcilquham@ohri.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05487274.